A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia

Journal of Psychiatric Research

Volumn 53, Issue 1, 2014, Pages 14-22

  Shen, Joan H Q ^a   Zhao, Yonggang ^b   Rosenzweig Lipson, Sharon ^c   Popp, Danielle ^d   Williams, Janet B W ^d,e   Giller, Earl ^d   Detke, Michael J ^f,g   Kane, John M ^h,i  

^a Shanghai Hengrui Pharmaceuticals Co Ltd   (China)

^b Skyview Research   (United States)

^c IVS Pharma Consulting   (United States)

^d MedAvante Inc   (United States)

^e Columbia University ^*  (United States)

^f Detke Biopharma Consulting LLC   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ZUCKER HILLSIDE HOSPITAL   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Central rater; Clinical trial; Olanzapine; Placebo; Schizophrenia; Vabicaserin

Indexed keywords

OLANZAPINE; PLACEBO; VABICASERIN; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; AGITATION; ARTICLE; ASTHMA; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONFUSION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPEPSIA; ESOPHAGITIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION IMPROVEMENT; HOMICIDE; HUMAN; HYPERTENSION; INCREASED APPETITE; INSOMNIA; KIDNEY FAILURE; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABSCESS; SOMNOLENCE; STOMACH DISCOMFORT; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; TOOTH PAIN; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA; YOUNG ADULT; ACUTE DISEASE; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPARATIVE STUDY; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897385077     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.02.012     Document Type: Article

References (16)

1. Dunlop J., Watts S.W., Barrett J.E., Coupet J., Harrison B., Mazandarani H., et al. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. JPharmacol Exp Ther 2011, 337:673-680.
2. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
3. Furukawa T.A., Akechi T., Wagenpfeil S., Leucht S. Relative indices of treatment effect may be constant across definitions of response in schizophrenia trials. Schizophr Res 2011, 126:212-219.
4. Guy W. Clinical global impressions. ECDEU assessment manual for psychopharmacology 1976, 218-222. National Institute of Mental Health, Rockville.
5. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
6. Marquis K.L., Dunlop J., Ramamoorhy S., Beyer C.E., Lin Q., Brennan J., et al. SCA-136, a novel 5-HT2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. Soc Neurosci 2006, 934.
7. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
8. Rosenzweig-Lipson S., Beyer C., Hughes Z., Lin Q., Zhang M.-Y., Grauer S., et al. Vabicaserin: effects of a novel 5-HT2C agonist on prefrontal cortical neurotransmission, cognition and sensorimotor gating. JEur Coll Neuropsychopharmacol 2007, 17(Suppl.4):S484.
9. Rosenzweig-Lipson S., Comery T.A., Marquis K.L., Gross J., Dunlop J. 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handb Exp Pharmacol 2012, 213:147-165.
10. Shen J., Kobak K.A., Zhao Y., Alexander M.M., Kane J.M. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. JClin Psychopharmacol 2008, 28:691-693.
11. Shen J., Preskorn S., Dragalin V., Slomkowski M., Padmanabhan S.K., Fardipour P., et al. How adaptive trial designs can increase efficiency in psychiatric drug development: a case study. Innov Clin Neurosci 2011, 8(7):26-34.
12. Shen J., Zhao Y., Rosenzweig-Lipson S., Popp D., Williams J.B.W., Giller E., et al. A6-week randomized, double-blind, placebo-controlled, comparator referenced, multicenter trial of vabicaserin in subjects with acute exacerbation of schizophrenia. Neuropsychopharmacology 2011, 36:S60.
13. Siuciak J.A., Chapin D.S., McCarthy S.A., Guanowsky V., Brown J., Chiang P., et al. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007, 52:279-290.
14. Wang R., Xu Y., Wu H.L., Li Y.B., Li Y.H., Guo J.B., et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 2008, 578:43-50.
15. Yoshino A., Shigemura J., Kobayashi Y., Nomura S., Shishikura K., Den R., et al. Telepsychiatry: assessment of televideo psychiatric review reliability with present- and next-generation internet infrastructures. Acta Psychiatr Scand 2001, 104:223-226.
16. Zarate C.A., Weinstock L., Cukor P., Moranito C., Leahy L., Burns C., et al. Applicability of telemedicine for assessing patients with schizophrenia: acceptance and reliability. JClin Psychiatry 1997, 58:22-25.